New data on new and newer drugs at the GU Cancers meeting

A whole host of new data on drugs like sipuleucel-T, enzalutamide, abiraterone, and others was available in the poster sessions at the Genitourinary Cancers Ssympisum in Orlando today. … READ MORE …

Aflibercept fails to extend survival of men with mCRPC in pivotal Phase III trial

Not entirely surprisingly, in a joint media release from Regeneron Pharmaceuticals and Sanofi issued yesterday, the two companies have announced that the investigational agent aflibercept did not extend overall survival in combination with docetaxel and prednisone in the randomized Phase III VENICE trial. … READ MORE …

Regeneron to continue VENICE trial of aflibercept

According to a media release from Regeneron Pharmaceuticals, the company plans to continue the randomized, multi-center, Phase III VENICE clinical trial, designed to evaluate the efficacy and safety of aflibercept (ZALTRAP™) in combination with docetaxel in the first-line treatment of patients with metastatic, hormone-refractory prostate cancer. … READ MORE …